Bruker acquires Noscendo’s DISQVER metagenomic sequencing platform

• Bruker acquired the DISQVER clinical metagenomics platform from Noscendo, expanding its NGS-based infection detection portfolio.
• DISQVER analyzes WGS data from cell-free blood samples to identify pathogens without prior cultivation, with results in under 24 hours.
• The software applies proprietary bioinformatics to screen for more than 11,000 microbes and parasites, targeting severe infections such as sepsis.
• DISQVER will remain research-use-only while Bruker pursues diagnostic registration.
• Financial terms were not disclosed; the deal is not expected to be material to Bruker’s FY26 results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260715763519) on July 15, 2026, and is solely responsible for the information contained therein.